Download PDF
Laryngorhinootologie 2008; 87(4): 237-243
DOI: 10.1055/s-2007-995588
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Stellenwert der Induktionstherapie bei Kopf-Hals-Tumoren

Current Role for Induction Chemotherapy in Head and Neck TumorsA.  Dietz1 , U.  Keilholz2 , J.  Werner3 , R.  Hagen4 , M.  Flentje5 , H.  Iro6
  • 1Klinik und Poliklinik für HNO-Heilkunde, plastische Operationen, Universitätsklinik Leipzig
  • 2Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin Charité, Berlin
  • 3HNO-Universitätsklinik Marburg
  • 4HNO-Universitätsklinik Würzburg
  • 5Strahlenklinik der Universität Würzburg
  • 6HNO-Universitätsklinik Erlangen
Further Information

Publication History

Publication Date:
26 March 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nach den aktuellen Publikationen im New England Journal of Medicine (TAX323, TAX324) der Studiengruppen um Jan Vermorken und Marschall Posner scheint die Induktionschemotherapie bei Plattenepithelkarzinomen des Kopf-Hals-Bereichs (im Näheren: Oro-Hypopharynx, Mundhöhle und Larynx) derzeit weltweit eine Renaissance zu erfahren. Renaissance deshalb, weil in den letzten Jahrzehnten das Thema in dieser Gruppe von Tumoren nach ausbleibender Überlebensverbesserung in der überwiegenden Mehrzahl von Studien wieder verlassen worden war. Es stellt sich die Frage, welche Entitäten von der Induktion, derzeit als Kombination von Docetaxel, Cisplatin und 5-Fluorouracil (TPF) empfohlen, profitieren? Dem ungebrochen hohen Stellenwert der Chirurgie mit ergänzender Bestrahlung bzw. Radiochemotherapie stand bislang die primäre Radiochemotherapie bei nicht resektablen Tumoren gegenüber. Derzeitige Studienaktivitäten versuchen, die Rolle der Induktionschemotherapie im aktuellen multimodalen Kontext zu klären.

Abstract

According to recent publications in the New England Journal of Medicine (TAX323, TAX324) of the study groups around Jan Vermorken and Marshall Posner induction chemotherapy in squamous cell carcinomas of the head-neck area (in the closer: Oro-hypopharynx, oral cavity and larynx) currently seems to generate a worldwide renaissance. Renaissance, because in the last few decades, induction chemo therapy in this group of tumors after lack of survival improvement in the vast majority of studies was again abandoned. The new data raise the question for which entities induction chemo therapy can be recommended (actually, a combination of docetaxel, cisplatin and 5-fluorouracil; TPF)? The unbroken high value of primary surgery with adjuvant radiation or chemo radiation was complementary to primary radio chemotherapy for non resectable tumors until today worldwide. Running studies are sorting out the role of induction chemotherapy in the current context of clarifying optimal multimodal treatment.

Schlüsselwörter

Induktionschemotherapie - Kopf-Hals-Tumore - Kehlkopf-Organerhalt - Chemoselektion

Key words

induction chemotherapy - chemo selection - head and neck tumor - organ preservation

Literatur

  • 1 Adelstein D, Saxton J, Lavertu P. et al . A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy aline in resectable stage III and IV squamous cell head and neck cancer: Preliminary results, chemoradiotherapy vs. radiotherapy.  Head Neck. 1997;  19 567-575
    CrossrefPubMedGoogle Scholar
  • 2 Adelstein D, Li Y, Adams G. et al . An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.  J Clin Oncol. 2003;  21 92-98
    CrossrefPubMedGoogle Scholar
  • 3 Bernier J, Schneider D. Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?.  Eur J Cancer. 2007;  43 35-45
    CrossrefPubMedGoogle Scholar
  • 4 Bonnano P C. Swallowing dysfunction after tracheotomy.  Ann Surg. 1971;  174 29-33
    PubMedGoogle Scholar
  • 5 Bonner J A, Harari P M, Giralt J, Azarnia N, Shin D M, Cohen R B, Jones C U, Sur R, Raben D, Jassem J, Ove R, Kies M S, Baselga J, Youssoufian H, Amellal N, Rowinsky E K, Ang K K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.  N Engl J Med. 2006;  354 567-578
    CrossrefPubMedGoogle Scholar
  • 6 Bourhis J, Overgaard J, Audry H, Ang K K, Saunders M, Bernier J, Horiot J C, Le Maitre A, Pajak T F, Poulsen M G, O’Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay J H, Pinto L H, Fallai C, Fu K K, Sylvester R, Pignon J P.. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group . Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.  Lancet. 2006;  368 843-854
    CrossrefPubMedGoogle Scholar
  • 7 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.  J Natl Cancer Inst. 1999;  91 2081-2086
    CrossrefPubMedGoogle Scholar
  • 8 Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, Bourhis J, Guerrif S, Garaud P. 2006 ASCO Annual Meeting Proceedings Part I.  Journal of Clinical Oncology. 2006;  Vol 24 No. 18 S (June 20 Supplement) 5506
    PubMedGoogle Scholar
  • 9 Cox J D, Stetz J, Pajak T. et al . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).  Int J Radiat Oncol Biol Phys. 1995;  31 1341-1346
    CrossrefPubMedGoogle Scholar
  • 10 Denis F, Garaud P, Bardet E. et al . Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced stage oropharynx carcinoma: Comparison of the LENT/SOMA, RTOG/EORTC, and the NCI-CTC scoring systems.  Int J Radiat Oncol Biol Phys. 2003;  55 93-98
    CrossrefPubMedGoogle Scholar
  • 11 Dietz A, Nollert J, Eckel H, Volling P, Schroder M, Staar S, Conradt C, Helmke B, Dollner R, Muller R P, Wannenmacher M, Weidauer H, Rudat V. Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie.  HNO. 2002;  50 146-154
    CrossrefPubMedGoogle Scholar
  • 12 Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H. Chronic laryngeal edema as a late reaction to radiochemotherapy.  HNO. 1998;  46 731-738
    CrossrefPubMedGoogle Scholar
  • 13 Dietz A, Rudat V, Hoppe F, Pfreundner L, Flentje M. Induction chemotherapy with paclitaxel and cisplatin, followed by accelerated-hyperfractionated radiotherapy in patients with advanced laryngeal and hypopharyngeal cancer - the DeLOS (Deutsche Larynxorganerhaltung-Studiengruppe)-trial Procedings. Berlin; Deutscher Krebskongress 2006
    Google Scholar
  • 14 Dische S, Warburton M, Jones D. et al . The recording of morbidity related to radiotherapy.  Radiat Oncol. 1989;  16 103-108
    PubMedGoogle Scholar
  • 15 Eibling D E, Gross R D. Subglottic air pressure: a key component of swallowing efficiency.  Ann Otol Rhinol Laryngol. 1996;  105 253-258
    PubMedGoogle Scholar
  • 16 Feldmann S A, Deal C W, Urquhart W. Disturbance of swallowing after tracheotomy.  Lancet. 1966;  1 954-955
    PubMedGoogle Scholar
  • 17 Forastiere A A, Goepfert H, Maor M, Pajak T F, Weber R, Morrison W, Glisson B, Trotti A, Ridge J A, Chao C, Peters G, Lee D J, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.  N Engl J Med. 2003;  349 2091-2098
    CrossrefPubMedGoogle Scholar
  • 18 Forastiere A A, Maor M, Weber R S. et al . Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. 2006 ASCO Annual Meeting Proceedings Part I.  Journal of Clinical Oncology. 2006;  24 5517
    PubMedGoogle Scholar
  • 19 Higgins D M, Maclean J C. Dysphagia in the patient with a tracheostomy: Six cases of inappropriate cuff deflation or removal.  Heart and Lung. 1997;  26 215-220
    PubMedGoogle Scholar
  • 20 Hillman R E, Walsh M J, Wolf G T, Fisher S G, Hong W K. Functional outcomes following treatment for advanced laryngeal cancer. Part I - Voice preservation in advanced laryngeal cancer. Part II - Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group.  Ann Otol Rhinol Laryngol. 1998;  Suppl 172 1-27
    PubMedGoogle Scholar
  • 21 Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega M E, Marti J L, Lobo F, Pastor P, Valenti V, Belon J, Sanchez M A, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L, Cortes-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.  J Clin Oncol. 2005;  23 8636-8645
    CrossrefPubMedGoogle Scholar
  • 22 Hoffman H T, Porter K, Karnell L H, Cooper J S, Weber R S, Langer C J, Ang K K, Gay G, Stewart A, Robinson R A. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival.  Laryngoscope. 2006;  116 1529-1542
    CrossrefPubMedGoogle Scholar
  • 23 Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.  J Clin Oncol. 2000;  18 1458-1464
    CrossrefPubMedGoogle Scholar
  • 24 Knecht R, Baghi M, Hambek M, Tesch H, Gstottner W. Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the first-line therapy of advanced head and neck carcinomas (SCCHN).  Proc Am Soc Clin Oncol. 2003;  22 501 (Abstract 2017)
    PubMedGoogle Scholar
  • 25 Lefebvre J L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.  J Natl Cancer Inst. 1996;  88 890-899
    CrossrefPubMedGoogle Scholar
  • 26 Mohide E A, Archibald S D, Tew M, Young J E, Haines T. Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals.  Am J Surg. 1992;  164 619-622
    PubMedGoogle Scholar
  • 27 Murray J. The laryngoscopic evaluation of swallowing or fees.  In: Murray J (ed). Manual of Dysphagia Assessment in Adults. Singular Publishing Group, Inc 1999: 153-190
    Google Scholar
  • 28 Nash M. Swallowing problems in tracheotomized patient.  Otolaryngol Clin North Am. 1988;  21 701-709
    PubMedGoogle Scholar
  • 29 NCI/CTC Web site .http://ctep.info.nih.gov
  • 30 Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, Helms J, Flentje M. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas - a possibility for organ preservation.  Radiother Oncol. 2003;  68 163-170
    CrossrefPubMedGoogle Scholar
  • 31 Pignon J P, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.  Lancet. 2000;  355 949-955
    CrossrefPubMedGoogle Scholar
  • 32 Posner M R, Hershock D M, Blajman C R, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin D M, Cullen K, Ervin T J, Murphy B A, Raez L E, Cohen R B, Spaulding M, Tishler R B, Roth B, Viroglio, Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter K W, Dugan M, Cmelak A, Markoe A M, Read P W, Steinbrenner L, Colevas A D, Norris Jr C M, Haddad R I.. TAX 324 Study Group . Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.  N Engl J Med. 2007;  357 1705-1715
    CrossrefPubMedGoogle Scholar
  • 33 Richard J M, Sancho-Garnier H, Pessey J J, Luboinski B, Lefebvre J L, Dehesdin D, Stromboni-Luboinski M, Hill C. Randomized trial of induction chemotherapy in larynx carcinoma.  Oral Oncol. 1998;  34 224-228
    CrossrefPubMedGoogle Scholar
  • 34 Rosenthal D I, Lewin J S, Eisbruch A. Dysphagia after radiation therapy or chemoradiation for head and neck cancer.  J Clin Oncol. 2006;  24 2636-2643
    Google Scholar
  • 35 Rubin P, Constine S, Fajardo L. et al . Overview of late effects of normal tissues (LENT-SOMA) scoring system.  Int J Radiat Oncol Biol Phys. 1995;  31 1041-1042
    CrossrefPubMedGoogle Scholar
  • 36 Shaker R, Milbarth M, Ren J, Campbell B, Toohill R, Hogan W. Deglutitive Aspiration with tracheostomy: Effect of Tracheostomy on the duration of vocal chord closure.  Gastroenterology. 1995;  108 154-159
    PubMedGoogle Scholar
  • 37 Simon C, Plinkert P K. Transoral resection of locally advanced squamous cell carcinoma of the side wall of the oropharynx: multimodal treatment concepts in transition.  Laryngoscope. 2006;  116 1529
    CrossrefPubMedGoogle Scholar
  • 38 Sticher H, Gratz C. Trachealkanülen-Management in der F. O. T. T. - Der Weg zurück zur Physiologie.  In: Nusser-Müller-Busch R (Hrsg). Die Therapie des Facio-Oralen Trakts. Berlin, Heidelberg; Springer 2004: 181-190
    Google Scholar
  • 39 Terrell J E, Fisher S G, Wolf G T. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group.  Arch Otolaryngol Head Neck Surg. 1998;  124 964-971
    CrossrefPubMedGoogle Scholar
  • 40 The Department of Veterans Affairs Laryngeal Cancer Study Group . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.  N Engl J Med. 1991;  324 1685-1690
    CrossrefPubMedGoogle Scholar
  • 41 Tolep K, Getch C L, Criner G J. Swallowing dysfunction in patients receiving prolonged mechanical ventilation.  Chest. 1996;  109 167-172
    CrossrefPubMedGoogle Scholar
  • 42 Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials.  J Clin Oncol. 2004;  22 19-22
    PubMedGoogle Scholar
  • 43 Vermorken J B, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart J S, Jelic S, Betka J, Preiss J H, van den Weyngaert D, Awada A, Cupissol D, Kienzer H R, Rey A, Desaunois I, Bernier J, Lefebvre J L.. EORTC 24 971/TAX 323 Study Group . Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.  N Engl J Med. 2007;  357 1695-1704
    CrossrefPubMedGoogle Scholar
  • 44 Waters T, Logemann J, Pauloski B. et al . Beyond efficacy and effectiveness: Conducting economic analyses during clinical trials.  Dysphagia. 2004;  19 109-119
    PubMedGoogle Scholar
  • 45 World Health Organization .WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland; WHO Offset publication No. 48 1979
    Google Scholar
  • 46 Wyke B D. Myotactic reflexogenic systems in the larynx.  Folia morphologica (Praha). 1973;  21 113-117
    PubMedGoogle Scholar

Univ.-Professor Dr. med. Andreas Dietz

Klinik und Poliklinik für Hals- Nasen- Ohrenheilkunde/Plastische Operationen

Universität Leipzig

Liebigstraße 10 - 14

04103 Leipzig

Email: andreas.dietz@medizin.uni-leipzig.de

URL: http://www.uni-leipzig.de/∼hno/

      >